vs

Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and VerifyMe, Inc. (VRME). Click either name above to swap in a different company.

VerifyMe, Inc. is the larger business by last-quarter revenue ($5.0M vs $4.8M, roughly 1.1× MAXCYTE, INC.). VerifyMe, Inc. runs the higher net margin — -66.7% vs -200.5%, a 133.8% gap on every dollar of revenue. On growth, VerifyMe, Inc. posted the faster year-over-year revenue change (-7.4% vs -20.9%). Over the past eight quarters, VerifyMe, Inc.'s revenue compounded faster (-5.2% CAGR vs -7.4%).

MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.

VerifyMe, Inc. is a technology provider specializing in identity verification, anti-counterfeiting, and brand protection solutions. Its offerings include secure authentication tools, supply chain traceability systems, and customer engagement platforms, serving consumer goods, pharmaceutical, and retail sectors across North America and select global markets.

MXCT vs VRME — Head-to-Head

Bigger by revenue
VRME
VRME
1.1× larger
VRME
$5.0M
$4.8M
MXCT
Growing faster (revenue YoY)
VRME
VRME
+13.5% gap
VRME
-7.4%
-20.9%
MXCT
Higher net margin
VRME
VRME
133.8% more per $
VRME
-66.7%
-200.5%
MXCT
Faster 2-yr revenue CAGR
VRME
VRME
Annualised
VRME
-5.2%
-7.4%
MXCT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
MXCT
MXCT
VRME
VRME
Revenue
$4.8M
$5.0M
Net Profit
$-9.6M
$-3.4M
Gross Margin
41.2%
Operating Margin
-234.5%
-68.2%
Net Margin
-200.5%
-66.7%
Revenue YoY
-20.9%
-7.4%
Net Profit YoY
9.4%
-38.4%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MXCT
MXCT
VRME
VRME
Q4 25
$4.8M
Q3 25
$4.6M
$5.0M
Q2 25
$5.8M
$4.5M
Q1 25
$5.7M
$4.5M
Q4 24
$6.1M
Q3 24
$5.6M
$5.4M
Q2 24
$5.0M
$5.4M
Q1 24
$5.6M
$5.8M
Net Profit
MXCT
MXCT
VRME
VRME
Q4 25
$-9.6M
Q3 25
$-12.4M
$-3.4M
Q2 25
$-12.4M
$-291.0K
Q1 25
$-10.3M
$-571.0K
Q4 24
$-10.6M
Q3 24
$-11.6M
$-2.4M
Q2 24
$-9.4M
$-346.0K
Q1 24
$-9.5M
$-553.0K
Gross Margin
MXCT
MXCT
VRME
VRME
Q4 25
Q3 25
41.2%
Q2 25
35.2%
Q1 25
33.4%
Q4 24
Q3 24
34.9%
Q2 24
39.1%
Q1 24
39.2%
Operating Margin
MXCT
MXCT
VRME
VRME
Q4 25
-234.5%
Q3 25
-307.4%
-68.2%
Q2 25
-244.3%
-7.1%
Q1 25
-214.1%
-13.3%
Q4 24
-213.1%
Q3 24
-250.4%
-52.8%
Q2 24
-241.0%
-10.0%
Q1 24
-219.8%
-11.2%
Net Margin
MXCT
MXCT
VRME
VRME
Q4 25
-200.5%
Q3 25
-269.7%
-66.7%
Q2 25
-212.2%
-6.4%
Q1 25
-178.7%
-12.8%
Q4 24
-175.0%
Q3 24
-205.9%
-44.6%
Q2 24
-188.8%
-6.5%
Q1 24
-170.6%
-9.6%
EPS (diluted)
MXCT
MXCT
VRME
VRME
Q4 25
Q3 25
$-0.12
$-0.26
Q2 25
$-0.12
$-0.02
Q1 25
$-0.05
Q4 24
Q3 24
$-0.11
$-0.23
Q2 24
$-0.09
$-0.03
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MXCT
MXCT
VRME
VRME
Cash + ST InvestmentsLiquidity on hand
$103.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$171.5M
$11.1M
Total Assets
$202.5M
$13.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MXCT
MXCT
VRME
VRME
Q4 25
$103.0M
Q3 25
$105.7M
Q2 25
$126.6M
Q1 25
$138.3M
Q4 24
$154.5M
Q3 24
$153.8M
$2.6M
Q2 24
$157.3M
$2.9M
Q1 24
$157.5M
$2.8M
Total Debt
MXCT
MXCT
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$500.0K
Q2 24
$600.0K
Q1 24
$800.0K
Stockholders' Equity
MXCT
MXCT
VRME
VRME
Q4 25
$171.5M
Q3 25
$180.3M
$11.1M
Q2 25
$190.7M
$14.4M
Q1 25
$199.4M
$14.6M
Q4 24
$206.3M
Q3 24
$213.3M
$10.3M
Q2 24
$221.3M
$12.3M
Q1 24
$226.4M
$12.4M
Total Assets
MXCT
MXCT
VRME
VRME
Q4 25
$202.5M
Q3 25
$213.5M
$13.3M
Q2 25
$219.8M
$17.2M
Q1 25
$230.0M
$17.1M
Q4 24
$239.5M
Q3 24
$248.6M
$14.8M
Q2 24
$251.5M
$17.5M
Q1 24
$257.9M
$17.9M
Debt / Equity
MXCT
MXCT
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.05×
Q2 24
0.05×
Q1 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MXCT
MXCT
VRME
VRME
Operating Cash FlowLast quarter
$-2.7M
$243.0K
Free Cash FlowOCF − Capex
$-2.9M
FCF MarginFCF / Revenue
-61.0%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-36.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MXCT
MXCT
VRME
VRME
Q4 25
$-2.7M
Q3 25
$-7.5M
$243.0K
Q2 25
$-9.9M
$710.0K
Q1 25
$-14.4M
$-404.0K
Q4 24
$-7.8M
Q3 24
$-4.4M
$-10.0K
Q2 24
$-4.8M
$372.0K
Q1 24
$-10.6M
$-60.0K
Free Cash Flow
MXCT
MXCT
VRME
VRME
Q4 25
$-2.9M
Q3 25
$-7.8M
Q2 25
$-10.4M
Q1 25
$-15.1M
Q4 24
$-8.0M
Q3 24
$-4.8M
$-12.0K
Q2 24
$-5.1M
$369.0K
Q1 24
$-11.4M
$-62.0K
FCF Margin
MXCT
MXCT
VRME
VRME
Q4 25
-61.0%
Q3 25
-168.5%
Q2 25
-179.2%
Q1 25
-262.3%
Q4 24
-131.6%
Q3 24
-85.5%
-0.2%
Q2 24
-103.3%
6.9%
Q1 24
-203.6%
-1.1%
Capex Intensity
MXCT
MXCT
VRME
VRME
Q4 25
4.8%
Q3 25
6.5%
Q2 25
10.0%
Q1 25
11.4%
Q4 24
2.4%
Q3 24
7.2%
0.0%
Q2 24
5.9%
0.1%
Q1 24
14.4%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MXCT
MXCT

Products$4.2M87%
Other$634.0K13%

VRME
VRME

Proactive Services$4.2M83%
Other$869.0K17%

Related Comparisons